Author

Irina Nesterenko

Observed names: I Nesterenko, Nesterenko, I

Observed institutions: Harvard University, University of California, Irvine, Massachusetts General Hospital

OpenAlex ID: A5007309877

Antiangiogenic Variant of TSP-1 Targets Tumor Cells in Glioblastomas

2014 · Sung Hugh Choi, Kaoru Tamura, et al. · Molecular Therapy · 56

CRISPR-enhanced engineering of therapy-sensitive cancer cells for self-targeting of primary and metastatic tumors

2018 · Clemens Reinshagen, Deepak Bhere, et al. · Science Translational Medicine · 49

Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma

2016 · J M Thompson, Q H Nguyen, et al. · Oncogene · 42

A First-Generation Multi-Functional Cytokine for Simultaneous Optical Tracking and Tumor Therapy

2012 · Shawn Hingtgen, Randa Kasmieh, et al. · PLoS ONE · 32

Evaluating the Effect of Therapeutic Stem Cells on TRAIL Resistant and Sensitive Medulloblastomas

2012 · Irina Nesterenko, Simone Wanningen, et al. · PLoS ONE · 25

Antiangiogenic Variant of TSP-1 Targets Tumor Cells in Glioblastomas

2024 · Sung Hugh Choi, Kaoru Tamura, et al. · Molecular Therapy · 2

Promoting Awareness and Early Detection of Breast Cancer in Thailand

2010 · Aneliya Z Rankova, Irina Nesterenko, et al. · Digital WPI · 2

Antiangiogenic Variant of TSP-1 Targets Tumor Cells in Glioblastomas

2024 · Sung Hugh Choi, Kaoru Tamura, et al. · Molecular Therapy

Abstract PR15: Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma

2017 · Jordan M. Thompson, Quy H. Nguyen, et al. · Molecular Cancer Therapeutics

Sensitizing Medulloblastoma Cells to Stem Cell-Delivered TRAIL Using an HDAC Inhibitor

2011 · Irina Nesterenko · Digital WPI

Works count: 12

Citation count: 208

H-index: 5

I10-index: 5